PKI 14-22 amide,myristoylated
Based on 3 publication(s) in Google Scholar
PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with Ki=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs.
For research use only. We do not sell to patients.
- Purity: 98.96%
- CAS No.: 201422-03-9
- Formula: C53H100N20O12
- Molecular Weight:1209.49
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15979
H-89
-
HY-N6789
KT5720
-
HY-12306A
8-Bromo-cAMP
-
HY-15371
Forskolin
-
HY-13818
Stattic
-
HY-108882
DNase I, Bovine pancreas
-
HY-P1290
PKA Inhibitor Fragment (6-22) amide
-
HY-112461A
NF449 octasodium
-
HY-15979A
H-89 dihydrochloride
-
HY-P0222
PKI(5-24)
-
HY-P0248
Kemptide
-
HY-P0215
Autocamtide-2-related inhibitory peptide, myristoylated
Publications Citing Use of MedChemExpress (MCE) PKI 14-22 amide,myristoylated
More
Biological Activity
|
Zika virus |
PKI 14-22 amide,myristoylated (20-40 μM; 72 h) significantly inhibits Zika virus replication in HUVEC and astrocytes, reducing viral titers by more than 85% without causing significant cytotoxicity[2].
PKI 14-22 amide,myristoylated (10-40 μM; 4-24 h) inhibits viral structural protein (capsid/NS1) expression and positive and negative strand RNA synthesis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVEC
-
Concentration:10 μM, 20 μM, 40 μM
-
Incubation Time:48-72 h
-
Result:Significantly reduced expression of viral capsid and NS1 proteins in a dose-dependent manner.
At 40 μM, protein levels were undetectable by 72 hpi, while 10 μM showed partial inhibition.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Swiss Webster mice (25-30 g, 6 weeks), morphine tolerance model via 75 mg pellet implantation[3]
-
Dosage:5 nmol/mouse
-
Administration:1 dose (1 h before pellet implantation) + 2 additional doses at 24 h and 48 h post-implantation, total 3 doses over 3 days.
-
Result:In the tail immersion test, morphine-pelleted mice pre-treated with PKI showed no tolerance to morphine’s antinociceptive effect, with ED50 values comparable to naive mice (6.2 vs. 6.6 mg/kg, non-significant difference).
Chemical Information
-
CAS No. 201422-03-9
-
Appearance Solid
-
Molecular Weight 1209.49
-
Formula C53H100N20O12
-
Color White to off-white
-
Sequence Shortening
Myristoyl-GRTGRRNAI-NH2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
J Mol Histol
Identification of the oncogenic role of centromere protein M in non-small cell lung cancer via CDC20/MYBL2/Wnt signaling pathways. [Abstract]2025 Apr 26;56(3):144. PMID: 40285932 -
-
Solvent & Solubility
H2O : 50 mg/mL (41.34 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. L Ydrenius, et al. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol. 2000 Apr;67(4):520-8. [Content Brief]
[2]. Cheng F, et al. Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol. 2018 Jan 30;92(4):e02019-17. [Content Brief]
[3]. Gabra BH, et al. Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res. 2008 Jun 27;1217:70-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.8268 mL | 4.1340 mL | 8.2679 mL | 20.6699 mL |
| 5 mM | 0.1654 mL | 0.8268 mL | 1.6536 mL | 4.1340 mL | |
| 10 mM | 0.0827 mL | 0.4134 mL | 0.8268 mL | 2.0670 mL | |
| 15 mM | 0.0551 mL | 0.2756 mL | 0.5512 mL | 1.3780 mL | |
| 20 mM | 0.0413 mL | 0.2067 mL | 0.4134 mL | 1.0335 mL | |
| 25 mM | 0.0331 mL | 0.1654 mL | 0.3307 mL | 0.8268 mL | |
| 30 mM | 0.0276 mL | 0.1378 mL | 0.2756 mL | 0.6890 mL | |
| 40 mM | 0.0207 mL | 0.1033 mL | 0.2067 mL | 0.5167 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
PKI 14-22 amide,myristoylated Related Classifications
HY-P1291 Related Classifications
Powered by Bioz